Structure Therapeutics, Inc. (GPCR)
17.36
-0.81
(-4.46%)
USD |
NASDAQ |
Nov 18, 16:00
17.43
+0.07
(+0.40%)
After-Hours: 20:00
Structure Therapeutics Debt to Equity Ratio : 0.0056 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.0056 |
| June 30, 2026 | 0.0046 |
| March 31, 2026 | 0.004 |
| December 31, 2025 | 0.0043 |
| September 30, 2025 | 0.0092 |
| June 30, 2025 | 0.0099 |
| March 31, 2025 | 0.0092 |
| December 31, 2024 | 0.0045 |
| September 30, 2024 | 0.0049 |
| June 30, 2024 | 0.0051 |
| Date | Value |
|---|---|
| March 31, 2024 | 0.0119 |
| December 31, 2023 | 0.012 |
| September 30, 2023 | 0.02 |
| June 30, 2023 | 0.0003 |
| March 31, 2023 | 0.0007 |
| December 31, 2022 | 0.0031 |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | 0.0061 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Eli Lilly & Co. | 1.229 |
| Novo Nordisk A/S | 0.6174 |
| Merck & Co., Inc. | 1.198 |
| Prestige Consumer Healthcare, Inc. | 1.094 |
| Pfizer Inc. | 0.7042 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 1.334B |
| Total Liabilities (Quarterly) | 112.55M |
| Shareholders Equity (Quarterly) | 1.222B |
| Current Ratio | 11.91 |
| Net Debt Paydown Yield | 0.01% |